Skip to main content

Table 3 Adverse events

From: Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

  Before TCZ initiation (N = 60) After TCZ initiation (N = 60)
AEs reported in ≥ 2 patients, n (%)
 AEs attributed to glucocorticoids
  Cataract 3 (5.0) 4 (6.7)
  Impaired glucose metabolism 5 (8.3) 3 (5.0)
  Psychiatric complications* 9 (15.0) 1 (1.7)
  Gastroesophageal reflux disease 3 (5.0) 0
  Gastrointestinal hemorrhage 1 (1.7) 2 (3.3)
  Myopathy 4 (6.7) 1 (1.7)
  Osteopenia 5 (8.3) 1 (1.7)
  Atrial fibrillation 1 (1.7) 2 (3.3)
  Hypertension 1 (1.7) 2 (3.3)
  Cardiac failure 2 (3.3) 0
 AEs attributed to glucocorticoids and/or TCZ
  Dyslipidemia 0 2 (3.3)
  Pneumonia 4 (6.7) 4 (6.7)
  Urinary tract infection 1 (1.7) 2 (3.3)
  Sinusitis 0 2 (3.3)
  Herpes zoster infection 2 (3.3) 1 (1.7)
 AEs attributed to TCZ
  Leukopenia 0 3 (5.0)
  Thrombocytopenia 0 2 (3.3)
  Increased transaminases 0 3 (5.0)
 AEs unrelated to glucocorticoids and/or TCZ
  Osteoarthritis 0 3 (5.0)
  Musculoskeletal pain 0 3 (5.0)
  Deep vein thrombosis 0 2 (3.3)
  Lumbar radiculopathy 0 2 (3.3)
SAEs reported in ≥ 1 patient, n (%) 6 (10.0) 6 (10.0)
 SAEs attributed to glucocorticoids
  Diabetic ketoacidosis 0 1 (1.7)
  Gastrointestinal hemorrhage 0 2 (3.3)
  Osteoporotic hip fracture 1 (1.7) 0
  Depression 1 (1.7) 0
  Atrial fibrillation 1 (1.7) 1 (1.7)
  Cardiac failure 2 (3.3) 0
 SAEs attributed to glucocorticoids and/or TCZ
  Pneumocystis jiroveci pneumonia 1 (1.7) 0
  Sepsis 0 1 (1.7)
 SAEs attributed to TCZ
  Leukopenia 0 1 (1.7)
  Intestinal perforation 0 1 (1.7)
 SAEs unrelated to glucocorticoids and/or TCZ
  Acute kidney injury 0 1 (1.7)
  Leiomyosarcoma 0 1 (1.7)
  Pneumonitis 1 (1.7) 0
  Pulmonary embolism 1 (1.7) 0
  1. AE adverse event, SAE serious adverse event, TCZ tocilizumab
  2. *Psychiatric complications included depression, worsening depression, insomnia, mood swings, and psychosis